Matthew J Martin

4PUBLICATIONS
37CO-AUTHORS
Haematological tumoursMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 29, 2026
AZ'4331 is a novel pan-TEAD auto-palmitoylation inhibitor for the treatment of Hippo pathway-altered cancers.

|Apr 17, 2024
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Ursula Grazini, Aleksandra Markovets, Lucy Ireland

|Mar 27, 2023
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells.

Matthew J Martin, Nicolas Floc'h, Matthias Pfeifer

|Sep 18, 2020
Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I.

Nicolas Floc'h, Sangbin Lim, Sue Bickerton

Pageof 1

Frequent Collaborators

2 joint publications

Matthias Pfeifer

2 joint publications

Paul D Smith

2 joint publications

Man Xu

2 joint publications

Nicolas Floc'h